Skip to main content

Qiming Venture Partners VI, L.P.'s Form 4 filing

Alamar Biosciences, Inc.ALMR · filed Oct 21, 2026

Accession no.
0001231919-26-001485
Filed
Oct 21, 2026, 7:15 PM ET
Trade date
Oct 19-20, 2026
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 16 non-derivative transactions. Open-market sales total $5.95M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Qiming Venture Partners VI, L.P.CIK 000173327810% Owner
Qiming Managing Directors Fund VI, L.P.CIK 000173328210% Owner
Qiming Venture Partners VIII-HC, L.P.CIK 000191002510% Owner
Qiming Corporate GP VI, Ltd.CIK 000205912710% Owner
Qiming Venture Partners VIII Investments, LLCCIK 000212961810% Owner
Qiming GP VIII-HC, LLCCIK 000212967110% Owner
Qiming GP VIII, LLCCIK 000212974010% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Oct 19, 2026Common StockSSaleDisposed−1,320$26.34F1−$34,768.8180,808Indirect
Oct 19, 2026Common StockSSaleDisposed−49,044$26.34F1−$1,291,818.966,719,561Indirect
Oct 19, 2026Common StockSSaleDisposed−11,443$26.34F1−$301,408.621,567,881Indirect
Oct 19, 2026Common StockSSaleDisposed−13,701$26.34F1−$360,884.341,877,116Indirect
Oct 20, 2026Common StockSSaleDisposed−200$26.63F6−$5,326180,608Indirect
Oct 20, 2026Common StockSSaleDisposed−1,947$27.93F7−$54,379.71178,661Indirect
Oct 20, 2026Common StockSSaleDisposed−335$28.44F8−$9,527.4178,326Indirect
Oct 20, 2026Common StockSSaleDisposed−7,415$26.63F6−$197,461.456,712,146Indirect
Oct 20, 2026Common StockSSaleDisposed−72,373$27.93F7−$2,021,377.896,639,773Indirect
Oct 20, 2026Common StockSSaleDisposed−12,447$28.44F8−$353,992.686,627,326Indirect
Oct 20, 2026Common StockSSaleDisposed−1,730$26.63F6−$46,069.91,566,151Indirect
Oct 20, 2026Common StockSSaleDisposed−16,887$27.93F7−$471,653.911,549,264Indirect
Oct 20, 2026Common StockSSaleDisposed−2,904$28.44F8−$82,589.761,546,360Indirect
Oct 20, 2026Common StockSSaleDisposed−2,072$26.63F6−$55,177.361,875,044Indirect
Oct 20, 2026Common StockSSaleDisposed−20,217$27.93F7−$564,660.811,854,827Indirect
Oct 20, 2026Common StockSSaleDisposed−3,477$28.44F8−$98,885.881,851,350Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.2 to $26.52, inclusive. The reporting person undertakes to provide to Alamar Biosciences, Inc., any security holder of Alamar Biosciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes (1) through (4) to this Form 4.

Referenced by the price of 4 transactions in Table I.

F6

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.20 to $26.96, inclusive.

Referenced by the price of 4 transactions in Table I.

F7

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.28 to $28.27, inclusive.

Referenced by the price of 4 transactions in Table I.

F8

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.28 to $28.73, inclusive.

Referenced by the price of 4 transactions in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)